RecruitingPhase 1NCT06708845

US Zamto-cel Autoimmune Diseases

A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects With Severe Refractory Autoimmune Diseases

Sponsor

Miltenyi Biomedicine GmbH

Enrollment

48 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus Diffuse Cutaneous Systemic Sclerosis Systemic Sclerosis (SSc)Lupus Nephritis

Summary

AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cyclophosphamide, a drug called Fludarabine, and others for people with diffuse cutaneous systemic sclerosis, lupus nephritis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALzamtocabtagene autoleucel

chimeric antigen receptor T-cell (CAR-T) therapy

DRUGCyclophosphamide

Lymphodepleting chemotherapy

DRUGFludarabine

Lymphodepleting chemotherapy

Locations(1)

Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06708845

Related Trials

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

NCT0761121415 locations

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325230 locations

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT0381634552 locations

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181139 locations

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT076079645 locations